IL292238A - Sequences of clec12a antibody fragments and methods - Google Patents

Sequences of clec12a antibody fragments and methods

Info

Publication number
IL292238A
IL292238A IL292238A IL29223822A IL292238A IL 292238 A IL292238 A IL 292238A IL 292238 A IL292238 A IL 292238A IL 29223822 A IL29223822 A IL 29223822A IL 292238 A IL292238 A IL 292238A
Authority
IL
Israel
Prior art keywords
methods
antibody fragment
fragment sequences
clec12a antibody
clec12a
Prior art date
Application number
IL292238A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of IL292238A publication Critical patent/IL292238A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL292238A 2019-10-17 2022-04-13 Sequences of clec12a antibody fragments and methods IL292238A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962916340P 2019-10-17 2019-10-17
PCT/US2020/055468 WO2021076545A1 (en) 2019-10-17 2020-10-14 Clec12a antibody fragment sequences and methods

Publications (1)

Publication Number Publication Date
IL292238A true IL292238A (en) 2022-06-01

Family

ID=75538859

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292238A IL292238A (en) 2019-10-17 2022-04-13 Sequences of clec12a antibody fragments and methods

Country Status (10)

Country Link
US (1) US20240117053A1 (enExample)
EP (1) EP4045540A4 (enExample)
JP (1) JP7796414B2 (enExample)
KR (1) KR20220083760A (enExample)
CN (1) CN114929745B (enExample)
AU (1) AU2020368354B2 (enExample)
BR (1) BR112022007219A2 (enExample)
CA (1) CA3158111A1 (enExample)
IL (1) IL292238A (enExample)
WO (1) WO2021076545A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021268340A1 (en) * 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
CN115850476B (zh) * 2022-08-09 2023-09-05 合源康华医药科技(北京)有限公司 一种cll1抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536310B2 (en) * 2007-10-17 2013-09-17 Arca Biopharma, Inc. Antibodies to CLL-1
EP2245153A4 (en) * 2008-02-13 2011-06-22 Dyax Corp IMPROVED METHODS FOR PRODUCING SPECIFIC BINDING SAVINGS
JP2013508308A (ja) * 2009-10-23 2013-03-07 ガーバン インスティテュート オブ メディカル リサーチ 修飾可変ドメイン分子、ならびにその産生および使用方法
BR112015006824A2 (pt) * 2012-09-27 2017-07-04 Merus B V anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
CN103467599B (zh) * 2013-09-27 2015-06-17 中国农业科学院兰州兽医研究所 双峰驼源抗猪瘟兔化弱毒疫苗株e2抗原重链抗体vhh和用途
EP3529268B1 (en) * 2016-10-19 2025-02-26 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
MX2019012953A (es) * 2017-05-02 2020-02-12 Alligator Bioscience Ab Anticuerpo biespecifico contra ox40 y ctla-4.
WO2019108065A1 (en) * 2017-12-01 2019-06-06 Merus N.V. Use of bispecific antibody and il-15 for combination therapy
WO2019118918A1 (en) * 2017-12-15 2019-06-20 Aleta Biotherapeutics Inc. Cd19 variants
US11951129B2 (en) * 2018-01-09 2024-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Compositions and methods for targeting CLEC12A-expressing cancers

Also Published As

Publication number Publication date
KR20220083760A (ko) 2022-06-20
EP4045540A1 (en) 2022-08-24
JP7796414B2 (ja) 2026-01-09
CA3158111A1 (en) 2021-04-22
CN114929745B (zh) 2025-11-18
AU2020368354A1 (en) 2022-05-12
US20240117053A1 (en) 2024-04-11
WO2021076545A1 (en) 2021-04-22
JP2022553940A (ja) 2022-12-27
EP4045540A4 (en) 2023-11-08
AU2020368354B2 (en) 2026-08-13
BR112022007219A2 (pt) 2022-07-05
CN114929745A (zh) 2022-08-19

Similar Documents

Publication Publication Date Title
ZA202004494B (en) Anti-tmprss2 antibodies and antigen-binding fragments
IL275073A (en) Antibodies against TREM2 and related methods
IL269593A (en) Anti-ILT4 antibodies and antigen-binding fragments
IL272218A (en) ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS
GB2600599B (en) Anti-Tau antibody and use thereof
GB2570138B (en) System and methods
IL286603A (en) Treatment employing anti-il-13r antibody or binding fragment thereof
ZA202003858B (en) Monoclonal antibodies and methods for using same
SG11202100194VA (en) Antigen purification method
IL291082A (en) Anti-vsig4 antibody or antigen-binding fragment and uses thereof
ZA202210284B (en) Anti-trem1 antibodies and related methods
IL277296A (en) Antibodies against PFRH5 and their antigen-binding fragments
GB2585849B (en) Spectrometer and method
EP4045540A4 (en) CLEC12A ANTIBODY FRAGMENT SEQUENCES AND METHODS
GB201911130D0 (en) MAterials and methods
GB2572055B (en) Chute and method
IL290570A (en) Anti-cd19 antibodies and their use
HK40079168A (en) Clec12a antibody fragment sequences and methods
AU2020214762A1 (en) Antibody and functional fragment thereof
GB201914354D0 (en) Nucleotide sequence and related methods
SG11202106452YA (en) Methods for identifying epitopes and paratopes
GB201911629D0 (en) Materials and methods
GB201911147D0 (en) Materials and methods
GB201911133D0 (en) Materials and methods
GB201911135D0 (en) Materials and methods